The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

Sabita S. Soedamah-Muthu; Val Charlton-Menys; Weihang Bao; Casper Schalkwijk; Coen D. A. Stehouwer; Helen M. Colhoun; D. John Betteridge; Paul N. Durrington; Graham A. Hitman; H. Andrew W. Neil; Shona J. Livingstone; John H. Fuller; David A. DeMicco; Gregory M. Preston

doi:10.1177/1474651411425112

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

Sabita S. Soedamah-Muthu, Val Charlton-Menys, Weihang Bao, Casper Schalkwijk, Coen D. A. Stehouwer, Helen M. Colhoun, D. John Betteridge, Paul N. Durrington, Graham A. Hitman, H. Andrew W. Neil, Shona J. Livingstone, John H. Fuller, David A. DeMicco, Gregory M. Preston

Research output: Contribution to journal › Article › peer-review

Abstract

We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011.

Original language	English
Pages (from-to)	288-297
Number of pages	10
Journal	British Journal of Diabetes and Vascular Disease
Volume	11
Issue number	6
DOIs	https://doi.org/10.1177/1474651411425112
Publication status	Published - 2011

Access to Document

10.1177/1474651411425112

http://www.scopus.com/inward/record.url?scp=84855414845&partnerID=8YFLogxK

Cite this

Soedamah-Muthu, S. S., Charlton-Menys, V., Bao, W., Schalkwijk, C., Stehouwer, C. D. A., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Fuller, J. H., DeMicco, D. A., & Preston, G. M. (2011). The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. British Journal of Diabetes and Vascular Disease, 11(6), 288-297. https://doi.org/10.1177/1474651411425112

Soedamah-Muthu, Sabita S. ; Charlton-Menys, Val ; Bao, Weihang ; Schalkwijk, Casper ; Stehouwer, Coen D. A. ; Colhoun, Helen M. ; Betteridge, D. John ; Durrington, Paul N. ; Hitman, Graham A. ; Neil, H. Andrew W. ; Livingstone, Shona J. ; Fuller, John H. ; DeMicco, David A. ; Preston, Gregory M. / The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. In: British Journal of Diabetes and Vascular Disease. 2011 ; Vol. 11, No. 6. pp. 288-297.

@article{b839c5bf665c4861ba910598e1f5a9f5,

title = "The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease",

abstract = "We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. {\textcopyright} SAGE Publications 2011.",

author = "Soedamah-Muthu, {Sabita S.} and Val Charlton-Menys and Weihang Bao and Casper Schalkwijk and Stehouwer, {Coen D. A.} and Colhoun, {Helen M.} and Betteridge, {D. John} and Durrington, {Paul N.} and Hitman, {Graham A.} and Neil, {H. Andrew W.} and Livingstone, {Shona J.} and Fuller, {John H.} and DeMicco, {David A.} and Preston, {Gregory M.}",

year = "2011",

doi = "10.1177/1474651411425112",

language = "English",

volume = "11",

pages = "288--297",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",

publisher = "SAGE Publications Inc.",

number = "6",

}

Soedamah-Muthu, SS, Charlton-Menys, V, Bao, W, Schalkwijk, C, Stehouwer, CDA, Colhoun, HM, Betteridge, DJ, Durrington, PN, Hitman, GA, Neil, HAW, Livingstone, SJ, Fuller, JH, DeMicco, DA & Preston, GM 2011, 'The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease', British Journal of Diabetes and Vascular Disease, vol. 11, no. 6, pp. 288-297. https://doi.org/10.1177/1474651411425112

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. / Soedamah-Muthu, Sabita S.; Charlton-Menys, Val; Bao, Weihang; Schalkwijk, Casper; Stehouwer, Coen D. A.; Colhoun, Helen M.; Betteridge, D. John; Durrington, Paul N.; Hitman, Graham A.; Neil, H. Andrew W.; Livingstone, Shona J.; Fuller, John H.; DeMicco, David A.; Preston, Gregory M.

In: British Journal of Diabetes and Vascular Disease, Vol. 11, No. 6, 2011, p. 288-297.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

AU - Soedamah-Muthu, Sabita S.

AU - Charlton-Menys, Val

AU - Bao, Weihang

AU - Schalkwijk, Casper

AU - Stehouwer, Coen D. A.

AU - Colhoun, Helen M.

AU - Betteridge, D. John

AU - Durrington, Paul N.

AU - Hitman, Graham A.

AU - Neil, H. Andrew W.

AU - Livingstone, Shona J.

AU - Fuller, John H.

AU - DeMicco, David A.

AU - Preston, Gregory M.

PY - 2011

Y1 - 2011

N2 - We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011.

AB - We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011.

U2 - 10.1177/1474651411425112

DO - 10.1177/1474651411425112

M3 - Article

VL - 11

SP - 288

EP - 297

JO - British Journal of Diabetes and Vascular Disease

JF - British Journal of Diabetes and Vascular Disease

SN - 1474-6514

IS - 6

ER -

Soedamah-Muthu SS, Charlton-Menys V, Bao W, Schalkwijk C, Stehouwer CDA, Colhoun HM et al. The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. British Journal of Diabetes and Vascular Disease. 2011;11(6):288-297. https://doi.org/10.1177/1474651411425112

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

Abstract

Access to Document

Fingerprint

Cite this